سعر روزموند 0.5مجم 10 اقراص 2022

Repaglinide 0.5 mg tablets (Rosemond, Copad Pharma, Egypt), a short-acting glinide insulin secretagogue; box of 10 tablets.

• Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus; not for type 1 diabetes or diabetic ketoacidosis.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (5% or more): hypoglycaemia, upper respiratory infection, headache, sinusitis, arthralgia, nausea, diarrhoea and back pain.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant use of gemfibrozil.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to repaglinide or any inactive ingredients.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypoglycaemia: repaglinide can cause hypoglycaemia, which may be severe; risk increases with changes in meals or activity, other antidiabetic agents, and renal or hepatic impairment. Educate patients to recognise and manage it.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Not indicated for use in combination with NPH-insulin (serious cardiovascular events, myocardial ischaemia, reported in trials).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No clinical studies have established conclusive evidence of macrovascular risk reduction.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• GemfibrozilConcomitant use is contraindicated.DailyMed (U.S. National Library of Medicine)
• ClopidogrelAvoid concomitant use; if unavoidable start at 0.5 mg before each meal and do not exceed 4 mg/day total.DailyMed (U.S. National Library of Medicine)
• CyclosporineDo not exceed a total daily repaglinide dose of 6 mg and increase glucose monitoring.DailyMed (U.S. National Library of Medicine)

• Limited case data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; poorly controlled diabetes in pregnancy carries maternal and fetal risks. No teratogenicity in rats and rabbits.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No human milk data; present in animal milk. Because of the potential for hypoglycaemia in breastfed infants, use while breastfeeding is not recommended.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Repaglinide: Quick, short-acting stimulation of insulin release from pancreatic beta cells.